树突状细胞融合瘤诱导抗结肠转移癌免疫应答  

In vitro antitumor immune response induced by fusion of dendritic cells and metastatic colon cancer cells

作　　者：和宇[1] 王杉[1] 叶颖江[1] 许峰[1] 崔志荣[1] 

机构地区：[1]北京大学人民医院胃肠外科外科肿瘤研究室,北京大学第三医院icu100044

出　　处：《中华普通外科杂志》2006年第8期594-597,共4页Chinese Journal of General Surgery

基　　金：北京市科技计划资助项目(Y0204003040531)

摘　　要：目的检测结肠转移癌细胞SW620和树突状细胞(DC)融合构建的肿瘤疫苗对结肠转移癌细胞SW620及其同源结肠癌细胞SW480的杀伤作用。方法应用促融合剂50％聚乙二醇(PEG)对SW620细胞和从外周血单个核细胞(PBMC)诱生的DC进行融合,用流式细胞仪(FCM)分析其表型并检测融合效率,电镜及免疫细胞化学观察DC、SW620和融合细胞(DC／SW620)形态;51Cr释放法检测DC／SW620致敏CTL对SW620及SW480细胞的杀伤作用。结果从PBMC成功诱生出高表达HLA-ABC、HLA-DR、CD80、CD86、CD83的成熟DC,DC／SW620的融合效率达到27．12％。融合细胞兼具DC与肿瘤细胞的结构特点及免疫表型。51Cr释放法检测DC／SW620激活的CTL对SW620及SW480的杀伤作用强于各对照组(P<0．01)。结论DC与SW620细胞融合体外致敏自体T淋巴细胞能生成抗原特异CTL,对结肠转移癌细胞SW620及同源结肠癌细胞SW480有一定的杀伤作用。Objective To detect the antitumor activity against SW620 and syngenic colon cancer SW480 by a fusion of human metastatic colon cancer SW620 cells and human peripheral blood-derived dendritic cells（DCs）. Methods SW620 cells and human peripheral blood- derived DCs were fused with polyethylene glycol （PEG）. The fusion cells were confirmed by phenotypes determine, morphologic observation, and cytotoxic T lymphocyte response induced by the fusion were studied. Results Mature DCs with highly expressed surface markers （HLA-ABC, HLA-DR and CD80, CD86, CD83） were generated in vitro. The fusion of SW620 cells with DC resulted in a hybrid cell with morphologic as well as phenotypic characteristics of both DC and tumor cells. Flow cytometry showed that the highest fusion efficiency was 27. 12%. CTL assay demonstrated that the DC/SW620 fusion induced specific cytotoxic responses against the SW620 and SW480 cells. Conclusion The fusion of tumor cells with DCs induces tumor rejection.

关 键 词：癌症疫苗 结肠肿瘤 细胞融合 免疫疗法 

分 类 号：R735.35[医药卫生—肿瘤]